

Jacques Genest

List of Publications by Year in descending order

Source: [//exaly.com/author-pdf/8257850/publications.pdf](https://exaly.com/author-pdf/8257850/publications.pdf)

Version: 2024-02-01

106
papers

20,756
citations

65103

42
h-index

30691

103
g-index

115
all docs

115
docs citations

115
times ranked

28692
citing authors

#	ARTICLE	IF	CITATIONS
1	Increased FH-Risk-Score and Diabetes Are Cardiovascular Risk Equivalents in Heterozygous Familial Hypercholesterolemia. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2024, 44, 505-512.	4.7	3
2	Influence of Polygenic Background on the Clinical Presentation of Familial Hypercholesterolemia. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2024, 44, 1683-1693.	4.7	0
3	Docetaxel as a Model Compound to Promote HDL (High-Density Lipoprotein) Biogenesis and Reduce Atherosclerosis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2023, 43, 609-617.	4.7	1
4	Transient very low LDL-C levels: a legacy effect for cardiovascular prevention?. <i>European Heart Journal</i> , 2023, 44, 1418-1420.	2.3	3
5	Influence of the LDL-Receptor Genotype on Statin Response in Heterozygous Familial Hypercholesterolemia: Insights From the Canadian FH Registry. <i>Canadian Journal of Cardiology</i> , 2022, 38, 311-319.	1.7	10
6	Worldwide experience of homozygous familial hypercholesterolaemia: retrospective cohort study. <i>Lancet, The</i> , 2022, 399, 719-728.	12.1	85
7	Health-related quality of life in homozygous familial hypercholesterolemia: A systematic review and meta-analysis. <i>Journal of Clinical Lipidology</i> , 2022, 16, 52-65.	1.6	11
8	The Cholesterol Uptake Capacity: The search for scalable HDL function tests continues. <i>Atherosclerosis</i> , 2022, 345, 39-40.	0.8	0
9	Macrophage Jak2 deficiency accelerates atherosclerosis through defects in cholesterol efflux. <i>Communications Biology</i> , 2022, 5, 132.	4.5	6
10	Prevalence and Treatment of Familial Hypercholesterolemia and Severe Hypercholesterolemia in Older Adults in Ontario, Canada. <i>CJC Open</i> , 2022, 4, 739-747.	1.6	2
11	High-Density Lipoprotein and Cardiovascular Disease—Where do We Stand?. <i>Endocrinology and Metabolism Clinics of North America</i> , 2022, 51, 557-572.	3.3	3
12	Effect of the LDL receptor mutation type on incident major adverse cardiovascular events in familial hypercholesterolaemia. <i>European Journal of Preventive Cardiology</i> , 2022, 29, 2125-2131.	1.8	10
13	Recurrent acute coronary syndrome caused by a primary aortic valve sarcoma: grand rounds and literature review. <i>European Heart Journal - Case Reports</i> , 2022, 6, .	0.6	0
14	Dj1 deficiency protects against atherosclerosis with anti-inflammatory response in macrophages. <i>Scientific Reports</i> , 2021, 11, 4723.	3.4	2
15	Identification of Docetaxel as a Potential Drug to Promote HDL Biogenesis. <i>Frontiers in Pharmacology</i> , 2021, 12, 679456.	3.6	6
16	Sex Differences in the Presentation, Treatment, and Outcome of Patients With Familial Hypercholesterolemia. <i>Journal of the American Heart Association</i> , 2021, 10, e019286.	3.9	14
17	2021 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in Adults. <i>Canadian Journal of Cardiology</i> , 2021, 37, 1129-1150.	1.7	462
18	Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). <i>Lancet, The</i> , 2021, 398, 1713-1725.	12.1	162

#	ARTICLE	IF	CITATIONS
19	Familial Hypercholesterolemia-Risk-Score: A New Score Predicting Cardiovascular Events and Cardiovascular Mortality in Familial Hypercholesterolemia. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2021, 41, 2632-2640.	4.7	47
20	New Strategies to Promote Macrophage Cholesterol Efflux. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 795868.	2.5	8
21	No benefit of HDL mimetic CER-001 on carotid atherosclerosis in patients with genetically determined very low HDL levels. <i>Atherosclerosis</i> , 2020, 311, 13-19.	0.8	21
22	Evidence for improved survival with treatment of homozygous familial hypercholesterolemia. <i>Current Opinion in Lipidology</i> , 2020, 31, 176-181.	2.8	17
23	Lomitapide for treatment of homozygous familial hypercholesterolemia: The Québec experience. <i>Atherosclerosis</i> , 2020, 310, 54-63.	0.8	13
24	Prevalence of Familial Hypercholesterolemia Among the General Population and Patients With Atherosclerotic Cardiovascular Disease. <i>Circulation</i> , 2020, 141, 1742-1759.	9.3	327
25	The Lifelong Burden of Homozygous Familial Hypercholesterolemia. <i>Canadian Journal of Cardiology</i> , 2019, 35, 1419.e1-1419.e4.	1.7	4
26	How the Cow Ate the CABG. <i>Journal of the American College of Cardiology</i> , 2019, 74, 1187-1189.	5.6	0
27	Prediction of Familial Hypercholesterolemia in Patients at High Atherosclerotic Cardiovascular Disease Risk Using a Recently Validated Algorithm. <i>CJC Open</i> , 2019, 1, 190-197.	1.6	2
28	Smashing Low-Density Lipoprotein Levels and Preventing Coronary Allograft Vasculopathy: One Heart Transplant Patient at a Time. <i>Canadian Journal of Cardiology</i> , 2019, 35, 17-18.	1.7	1
29	HDL cholesterol and ASCVD risk stratification: A debate. <i>Atherosclerosis</i> , 2019, 283, 7-12.	0.8	45
30	ABCA1 Agonist Mimetic Peptide CS-6253 Induces Microparticles Release From Different Cell Types by ABCA1-Efflux-Dependent Mechanism. <i>Canadian Journal of Cardiology</i> , 2019, 35, 770-781.	1.7	14
31	Risk of Ischemic Stroke and Peripheral Arterial Disease in Heterozygous Familial Hypercholesterolemia: A Meta-Analysis. <i>Angiology</i> , 2019, 70, 726-736.	1.8	25
32	High-Density Lipoproteins and Inflammatory Diseases: Full Circle Ahead. <i>Clinical Chemistry</i> , 2019, 65, 607-608.	3.5	1
33	Chylomicrons: When you can't direct the wind, adjust the sail. <i>Atherosclerosis</i> , 2019, 283, 121-123.	0.8	1
34	Genetic testing for familial hypercholesterolemia: Impact on diagnosis, treatment and cardiovascular risk. <i>European Journal of Preventive Cardiology</i> , 2019, 26, 1262-1270.	1.8	39
35	Risk factors for cardiovascular disease in heterozygous familial hypercholesterolemia: A systematic review and meta-analysis. <i>Journal of Clinical Lipidology</i> , 2019, 13, 15-30.	1.6	52
36	Diabetes is associated with an increased risk of cardiovascular disease in patients with familial hypercholesterolemia. <i>Journal of Clinical Lipidology</i> , 2019, 13, 123-128.	1.6	26

#	ARTICLE	IF	CITATIONS
37	Severe xanthomatosis in heterozygous familial hypercholesterolemia. <i>Journal of Clinical Lipidology</i> , 2018, 12, 872-877.	1.6	25
38	Familial hypercholesterolemia: experience from the French-Canadian population. <i>Current Opinion in Lipidology</i> , 2018, 29, 59-64.	2.8	26
39	Desmocollin 1 is abundantly expressed in atherosclerosis and impairs high-density lipoprotein biogenesis. <i>European Heart Journal</i> , 2018, 39, 1194-1202.	2.3	21
40	Posttranslational modification of proprotein convertase subtilisin/kexin type 9 is differentially regulated in response to distinct cardiometabolic treatments as revealed by targeted proteomics. <i>Journal of Clinical Lipidology</i> , 2018, 12, 1027-1038.	1.6	11
41	Anxiety, depression, and health-related quality of life in heterozygous familial hypercholesterolemia: A systematic review and meta-analysis. <i>Journal of Psychosomatic Research</i> , 2018, 109, 32-43.	2.9	20
42	HDLs and the pathogenesis of atherosclerosis. <i>Current Opinion in Cardiology</i> , 2018, 33, 311-316.	1.9	19
43	Pathological significance of lipoprotein(a) in aortic valve stenosis. <i>Atherosclerosis</i> , 2018, 272, 168-174.	0.8	21
44	Imputation of Baseline LDL Cholesterol Concentration in Patients with Familial Hypercholesterolemia on Statins or Ezetimibe. <i>Clinical Chemistry</i> , 2018, 64, 355-362.	3.5	49
45	Membrane microdomains and the regulation of HDL biogenesis. <i>Current Opinion in Lipidology</i> , 2018, 29, 36-41.	2.8	13
46	Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial. <i>Lancet</i> , The, 2018, 391, 319-328.	12.1	657
47	Canadian Cardiovascular Society Position Statement on Familial Hypercholesterolemia: Update 2018. <i>Canadian Journal of Cardiology</i> , 2018, 34, 1553-1563.	1.7	113
48	Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). <i>Atherosclerosis</i> , 2018, 277, 234-255.	0.8	172
49	Familial hypercholesterolemia in Canada: Initial results from the FH Canada national registry. <i>Atherosclerosis</i> , 2018, 277, 419-424.	0.8	20
50	Simplified Canadian Definition for Familial Hypercholesterolemia. <i>Canadian Journal of Cardiology</i> , 2018, 34, 1210-1214.	1.7	65
51	Role of inflammation in the pathogenesis of atherosclerosis and therapeutic interventions. <i>Atherosclerosis</i> , 2018, 276, 98-108.	0.8	309
52	The Essential Role of Primary Caregiver in Early Detection of Familial Hypercholesterolemia and Cardiovascular Prevention. <i>Current Pediatric Reviews</i> , 2018, 13, 260-264.	0.8	0
53	Estrogen-associated severe hypertriglyceridemia with pancreatitis. <i>Journal of Clinical Lipidology</i> , 2017, 11, 297-300.	1.6	22
54	ATP binding cassette A1 (ABCA1) mediates microparticle formation during high-density lipoprotein (HDL) biogenesis. <i>Atherosclerosis</i> , 2017, 257, 90-99.	0.8	48

#	ARTICLE	IF	CITATIONS
55	Pooled Safety Analysis of Evolocumab in Over 6000 Patients From Double-Blind and Open-Label Extension Studies. <i>Circulation</i> , 2017, 135, 1819-1831.	9.3	72
56	Aortic Calcification Progression in Heterozygote Familial Hypercholesterolemia. <i>Canadian Journal of Cardiology</i> , 2017, 33, 658-665.	1.7	15
57	Familial Hypercholesterolemia: Awareness, Appraisal, and Action. <i>Canadian Journal of Cardiology</i> , 2017, 33, 298-299.	1.7	5
58	Effect of interleukin-1 β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. <i>Lancet</i> , The, 2017, 390, 1833-1842.	12.1	1,013
59	Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. <i>New England Journal of Medicine</i> , 2017, 377, 1119-1131.	30.1	6,669
60	Lipoprotein(a) Induces Human Aortic Valve Interstitial Cell Calcification. <i>JACC Basic To Translational Science</i> , 2017, 2, 358-371.	4.8	65
61	Estimating the prevalence of heterozygous familial hypercholesterolaemia: a systematic review and meta-analysis. <i>BMJ Open</i> , 2017, 7, e016461.	2.1	260
62	Novel Approaches for HDL-Directed Therapies. <i>Current Atherosclerosis Reports</i> , 2017, 19, 55.	4.8	10
63	High-Density Lipoproteins: Biology, Epidemiology, and Clinical Management. <i>Canadian Journal of Cardiology</i> , 2017, 33, 325-333.	1.7	41
64	Access Denied: The Controversy of Commercial Genetic Databases. <i>Canadian Journal of Cardiology</i> , 2016, 32, 1295-1296.	1.7	1
65	Monoclonal Antibodies for the Treatment of Hypercholesterolemia: Targeting PCSK9. <i>Canadian Journal of Cardiology</i> , 2016, 32, 1552-1560.	1.7	14
66	2016 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult. <i>Canadian Journal of Cardiology</i> , 2016, 32, 1263-1282.	1.7	802
67	Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel. <i>Lancet Diabetes and Endocrinology</i> , the, 2016, 4, 850-861.	11.3	343
68	Reducing Vascular Calcification by Anti-IL-1 β Monoclonal Antibody in a Mouse Model of Familial Hypercholesterolemia. <i>Angiology</i> , 2016, 67, 157-167.	1.8	45
69	Nonfasting Sample for the Determination of Routine Lipid Profile: Is It an Idea Whose Time Has Come?. <i>Clinical Chemistry</i> , 2016, 62, 428-435.	3.5	22
70	Diagnosis, Prevention, and Management of Statin Adverse Effects and Intolerance: Canadian Consensus Working Group Update (2016). <i>Canadian Journal of Cardiology</i> , 2016, 32, S35-S65.	1.7	205
71	Novel Apo E-Derived ABCA1 Agonist Peptide (CS-6253) Promotes Reverse Cholesterol Transport and Induces Formation of pre β -1 HDL In Vitro. <i>PLoS ONE</i> , 2015, 10, e0131997.	2.5	48
72	High density lipoproteins: Measurement techniques and potential biomarkers of cardiovascular risk. <i>BBA Clinical</i> , 2015, 3, 175-188.	3.9	145

#	ARTICLE	IF	CITATIONS
73	Severe hyperhomocysteinemia due to cystathionine β -synthase deficiency, and Factor V Leiden mutation in a patient with recurrent venous thrombosis. <i>Thrombosis Journal</i> , 2014, 12, 30.	2.1	4
74	Canadian Cardiovascular Society Position Statement on Familial Hypercholesterolemia. <i>Canadian Journal of Cardiology</i> , 2014, 30, 1471-1481.	1.7	94
75	Treatment options for low high-density lipoproteins. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2014, 21, 134-139.	2.4	12
76	Circulating levels of the vasoactive peptide urotensin II in patients with acute coronary syndrome and stable coronary artery disease. <i>Peptides</i> , 2014, 55, 151-157.	2.4	17
77	High-Density Lipoprotein Mediated Cellular Cholesterol Efflux in Acute Coronary Syndromes. <i>American Journal of Cardiology</i> , 2014, 113, 249-255.	1.6	52
78	Long-Term Effects of 4 Popular Diets on Weight Loss and Cardiovascular Risk Factors. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2014, 7, 815-827.	4.0	60
79	Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9): Lessons Learned from Patients with Hypercholesterolemia. <i>Clinical Chemistry</i> , 2014, 60, 1380-1389.	3.5	34
80	Apolipoprotein E derived HDL mimetic peptide ATI-5261 promotes nascent HDL formation and reverse cholesterol transport in vitro. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2014, 1841, 1498-1512.	2.6	25
81	The <i>WVVOX</i> Gene Modulates High-Density Lipoprotein and Lipid Metabolism. <i>Circulation: Cardiovascular Genetics</i> , 2014, 7, 491-504.	5.1	49
82	Apolipoprotein A-I Truncations in Chagas Disease Are Caused by Cruzipain, the Major Cysteine Protease of <i>Trypanosoma cruzi</i> . <i>American Journal of Pathology</i> , 2014, 184, 976-984.	4.1	10
83	Aortic calcification: Novel insights from familial hypercholesterolemia and potential role for the low-density lipoprotein receptor. <i>Atherosclerosis</i> , 2013, 226, 9-15.	0.8	130
84	APOE p.Leu167del mutation in familial hypercholesterolemia. <i>Atherosclerosis</i> , 2013, 231, 218-222.	0.8	88
85	High-Density Lipoprotein and Residual Cardiovascular Risk. <i>Journal of the American College of Cardiology</i> , 2013, 62, 1842-1844.	5.6	4
86	HDL, Atherosclerosis, and Emerging Therapies. <i>Cholesterol</i> , 2013, 2013, 1-18.	1.6	70
87	Genetics of Cholesterol Efflux. <i>Current Atherosclerosis Reports</i> , 2012, 14, 235-246.	4.8	18
88	The LDLR deficient mouse as a model for aortic calcification and quantification by micro-computed tomography. <i>Atherosclerosis</i> , 2011, 219, 455-462.	0.8	56
89	Membrane microdomains modulate oligomeric ABCA1 function: impact on apoA1-mediated lipid removal and phosphatidylcholine biosynthesis. <i>Journal of Lipid Research</i> , 2011, 52, 2043-2055.	4.2	30
90	HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial. <i>Lancet</i> , 2010, 376, 333-339.	12.1	224

#	ARTICLE	IF	CITATIONS
91	C-reactive protein: Risk factor, biomarker and/or therapeutic target?. Canadian Journal of Cardiology, 2010, 26, 41A-44A.	1.7	85
92	Aortic calcifications in familial hypercholesterolemia: Potential role of the low-density lipoprotein receptor gene. American Heart Journal, 2009, 157, 170-176.	3.1	30
93	Approach to the diagnosis and management of lipoprotein disorders. Current Opinion in Endocrinology, Diabetes and Obesity, 2009, 16, 132-140.	2.4	19
94	Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein. New England Journal of Medicine, 2008, 359, 2195-2207.	30.1	5,843
95	Disorders of high-density lipoprotein biogenesis. Annals of Medicine, 2008, 40, 39-47.	3.9	2
96	Quantitative Analysis of ABCA1-dependent Compartmentalization and Trafficking of Apolipoprotein A-I. Journal of Biological Chemistry, 2008, 283, 11164-11175.	3.5	53
97	Genetics of High-Density Lipoproteins. , 2007, , 465-490.		1
98	Combination of statin and ezetimibe for the treatment of dyslipidemias and the prevention of coronary artery disease. Canadian Journal of Cardiology, 2006, 22, 863-868.	1.7	19
99	The analysis by Manuel and colleagues creates controversy with headlines, not data. Cmaj, 2005, 172, 1033-1034.	4.1	4
100	Biogenesis and speciation of nascent apoA-I-containing particles in various cell lines. Journal of Lipid Research, 2005, 46, 1668-1677.	4.2	64
101	Effect of fenofibrate-mediated increase in plasma homocysteine on the progression of coronary artery disease in type 2 diabetes mellitus. American Journal of Cardiology, 2004, 93, 848-853.	1.6	50
102	High-density lipoproteins: multifunctional vanguards of the cardiovascular system. Expert Review of Cardiovascular Therapy, 2004, 2, 417-430.	1.6	14
103	Homocysteine-betaine interactions in a murine model of 5,10-methylenetetrahydrofolate reductase deficiency. FASEB Journal, 2003, 17, 1-25.	0.5	147
104	Prevention of Cardiovascular Ischemic Events. Circulation, 2003, 107, 2059-2065.	9.3	47
105	Genetics and Prevention: A New Look at High-Density Lipoprotein Cholesterol. Cardiology in Review, 2002, 10, 61-71.	1.4	19
106	Sex differences in treatment of familial hypercholesterolaemia: a meta-analysis. European Heart Journal, 0, , .	2.3	1